Active-ingredient Dossier
Dapagliflozin
Active-ingredient Dossier for Dapagliflozin (sodium-glucose cotransporter inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled…
- Brand: FORXIGA
- Brand: SIDAPVIA
- Brand: XIGDUO XR
- Brand: QTERN
- Brand: GLIXAFOR
- Brand: DAPAGLICIP
- Therapeutic area: Endocrinology
What is
Dapagliflozin Dapagliflozin is a sodium-glucose cotransporter inhibitor.
Australian brands containing Dapagliflozin
— SIDAPVIA — GLIXAFOR — MSN-DAPAGLIFLOZIN — QTERN — DAPAGLIFLOZIN — XIGDUO XR
Therapeutic areas
Dapagliflozin is registered in endocrinology (6 brands) and cardiology (1 brand).
Sponsor landscape
The ingredient is marketed by four sponsors: AstraZeneca, Seed Pharma, Sandoz, and Pharmacor.
PBS and regulatory activity
No brands containing dapagliflozin are listed on the PBS. The latest PBAC outcome for dapagliflozin was recorded on 1 March 2024, and the latest AusPAR was issued on 24 May 2024. Five brands have PBAC outcomes on record and two brands have AusPARs on record. In the 2024–25 fiscal year, government cost for dapagliflozin was $87,333,779.54 across 1,915,738 scripts.